): The University of Colorado Cancer Center is requesting continuing support for their participation in the Southwest Oncology Group (SWOG). The mission of the University of Colorado Cancer Center has, since it's founding, been the reduction of cancer mortality through basic laboratory research, moving scientific discoveries to the clinic through translational research, and the design, execution, and analysis of clinical trials. Their participation in SWOG has been an integral part of the mission of the University of Colorado Cancer Center. Institutional pilot studies conducted at the University of Colorado have been brought to the Group in the form of prospective randomized trials. SWOG members from the University of Colorado have and continue to contribute to the administrative, educational and scientific functions of SWOG. University of Colorado SWOG members are chairs or co-chairs of the following committees: Genitourinary (Dr. E. David Crawford), Blood and Marrow Transplantation (Dr. Elizabeth Shpall), GU Pathology (Dr. Gary Miller), and Lung Biology (Wilbur Franklin). Dr. Scott Bearman is Principal Investigator for SWOG and sits on the Board of Governors. In addition to these administrative contributions, University of Colorado Cancer Center members are coordinators or co-coordinators of 17 percent of the SWOG protocols activated during the previous grant period. Presently, University of Colorado members are important contributors to the Blood and Marrow Transplantation, Breast, Lung, and GU Committees. During the next five years they expect to continue to make important scientific and administrative contributions to those committees. In addition, they expect to contribute in other areas as well, including radiotherapy (Drs. Rachel Rabinovitch and Michael Weil), developmental therapeutics (Dr. Andrew Kraft), neuro-oncology (Dr. Bertrand Liang) and Cancer Control (Dr. Marie Wood). They are proud of our contributions to the Southwest Oncology Group and are committed to its mission. They expect their contributions to increase during the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA042777-11
Application #
2450544
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1998-01-21
Project End
2002-12-31
Budget Start
1998-01-21
Budget End
1998-12-31
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 222 publications